This article, with insights from Babu Boga, Vice President of Medicinal Chemistry and Xiang Li, President of the Chemical Division, BioDuro, was originally published in the DDW Fall 2025, pages 30-31. Visit the website: DDW Fall 2025

The pharmaceutical industry constantly seeks innovative methods to identify novel therapeutic agents. Traditional high-throughput screening (HTS) often faces challenges like high false-positive rates and limited chemical diversity. Fragment-based drug discovery (FBDD) offers a compelling alternative. FBDD utilizes small, low-molecular-weight chemical fragments (typically<300 Da) that bind weakly to a target protein. Their smaller size leads to higher ‘ligand efficiency’ and enables them to access cryptic binding pockets, resulting in higher hit rates than HTS. These identified fragment hits serve as ideal starting points for rational elaboration into potent and selective lead compounds, often yielding novel chemical scaffolds.    

Rational fragment library design

The success of any FBDD campaign hinges critically on the quality and design of its fragment library. Unlike the vast, diverse libraries used in HTS, FBDD libraries are typically smaller, ranging from hundreds to a few thousand compounds, and are meticulously curated. A common approach emphasizes a rational design strategy often guided by computational methods, such as fingerprint-based approaches, to ensure broad chemical space coverage and diversity. Fragments are selected to represent a broad spectrum of key chemical functionalities essential for molecular recognition, including various hydrogen bond donors and acceptors, hydrophobic centers, aromatic rings, and ionizable groups, ensuring the library can probe diverse interaction types within a binding site.

The library is also designed to achieve broad coverage of chemical space in terms of molecular shape and physicochemical properties, ensuring that fragments with different geometries and interaction profiles can effectively sample and fit into various contours of the target’s binding pockets. Crucially, fragments are designed with “growth vectors”, which are specific, synthetically tractable sites or functional groups that can be readily elaborated or modified in subsequent optimization steps without disrupting the initial, weak binding interaction. This foresight significantly streamlines the fragment-to-lead optimization process. Beyond computational design principles, fragments are also rigorously filtered based on “Rule of 3” criteria (molecular weight<300 Da, cLogP <3, hydrogen bond donors <3, hydrogen bond acceptors <3, rotatable bonds <3). Adherence to these guidelines ensures good aqueous solubility, chemical stability, and synthetic accessibility, all of which are paramount for successful downstream development and eventual drug-likeness.

Structural elucidation

Critical structural characterization follows fragment hit identification. Precise, atomic level understanding of each fragment’s binding mode is paramount for rational optimization and lead generation, preventing empirical and inefficient processes.

X-ray Crystallography (XRC) remains the gold standard for elucidating atomic-level fragment protein interactions. Through co-crystallization, it provides an unambiguous three-dimensional map of the binding site, revealing specific interactions (e.g., hydrogen bonds, hydrophobic contacts, π-stacking) and, crucially, identifying unoccupied pockets or ‘hotspots’ for growth. While traditionally applied to larger macromolecular complexes, recent advancements in Cryo-Electron Microscopy (Cryo-EM) resolution are making it increasingly viable for structural determination of protein-ligand complexes, particularly for challenging targets that are difficult to crystallize or are membrane proteins. For targets amenable to solution-state studies, NMR can complement XRC by providing insights into dynamic interactions, conformational changes, and the presence of multiple binding poses that might not be captured in a static crystal structure.

• X-ray Crystallography (XRC): The gold standard for generating unambiguous 3D maps of binding sites and identifying hotspots for fragment growth.
• Cryo-Electron Microscopy (Cryo-EM): Enables high-resolution structural determination for challenging targets, including membrane proteins and those difficult to crystallize.
• NMR Spectroscopy: Complementary solution-state analysis to capture dynamic interactions, conformational changes, and multiple binding poses.

Fragment-to-lead optimization

With precise structural insights into fragment binding, the focus shifts to optimizing these initial hits into more selective, drug-like lead compounds. This iterative phase employs strategic approaches: Fragment growing systematically adds chemical moieties to the initial fragment, extending into adjacent, unoccupied pockets identified by structural analysis. This aims to improve affinity and selectivity through new interactions while maintaining the original fragment’s core binding. Fragment linking covalently joins two or more distinct fragments binding to separate but adjacent sites, often resulting in a significant, synergistic affinity increase from multiple interaction points. Alternatively, when two fragments are found to bind to overlapping regions of the binding site, they can be merged into a single, more potent molecule. This new compound incorporates the key binding features and favorable interactions of both initial fragments into a single, optimized scaffold. This optimization process is highly iterative, involving cycles of design, synthesis, biological evaluation, and further structural characterization.

“Fragment-Based Drug Discovery represents a paradigm shift in drug discovery, offering an efficient, rational pathway to novel chemical leads.”

Julian Williams | President of the Chemical Division, BioDuro

Conclusion

Fragment-Based Drug Discovery represents a paradigm shift in drug discovery, offering an efficient, rational pathway to novel chemical leads. This workflow, encompassing rational fragment design, sensitive biophysical screening, high resolution structural elucidation, and computationally-informed optimization, provides a robust and systematic framework.